Oxford BioDynamics (LSE:OBD) Short Percentage of Float


What is Oxford BioDynamics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LSE:OBD vs TMO, DHR, IDXX: Short Percentage of Float Comparison

For the Diagnostics & Research subindustry, Oxford BioDynamics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxford BioDynamics Short Percentage of Float vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Oxford BioDynamics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Oxford BioDynamics's Short Percentage of Float falls into.


Oxford BioDynamics Business Description

Other Exchanges OXBOF:USALMQ:Germany
Address John Smith Drive, 3140 Rowan Place, Oxford Business Park South, Oxford, GBR, OX4 2WB
Oxford BioDynamics PLC is a biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for serious and impactful diseases. The company is engaged in the commercialisation of proprietary molecular diagnostics products and biomarker research and development. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The company generates revenue from the sales of proprietary products and biomarker research and development. Geographically, it generates the maximum revenue from the USA.